CN100448479C - 化合物psi在制备治疗白血病药物中的应用 - Google Patents
化合物psi在制备治疗白血病药物中的应用 Download PDFInfo
- Publication number
- CN100448479C CN100448479C CNB2005101021947A CN200510102194A CN100448479C CN 100448479 C CN100448479 C CN 100448479C CN B2005101021947 A CNB2005101021947 A CN B2005101021947A CN 200510102194 A CN200510102194 A CN 200510102194A CN 100448479 C CN100448479 C CN 100448479C
- Authority
- CN
- China
- Prior art keywords
- psi
- cell
- leukemia
- medicine
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005101021947A CN100448479C (zh) | 2005-12-09 | 2005-12-09 | 化合物psi在制备治疗白血病药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005101021947A CN100448479C (zh) | 2005-12-09 | 2005-12-09 | 化合物psi在制备治疗白血病药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1824288A CN1824288A (zh) | 2006-08-30 |
CN100448479C true CN100448479C (zh) | 2009-01-07 |
Family
ID=36935233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005101021947A Expired - Fee Related CN100448479C (zh) | 2005-12-09 | 2005-12-09 | 化合物psi在制备治疗白血病药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100448479C (zh) |
-
2005
- 2005-12-09 CN CNB2005101021947A patent/CN100448479C/zh not_active Expired - Fee Related
Non-Patent Citations (11)
Title |
---|
21)+AML-M2的最大特征. 沈美凤,薛永权.国外医学输血及血液学分册,第21卷第1期. 1998 |
HL-60细胞属AML-M2型,NB4细胞为真正的AML-M3型. 何小庆,韩锐.中华血液学杂志,第17卷第5期. 1996 |
HL-60细胞属AML-M2型,NB4细胞为真正的AML-M3型. 何小庆,韩锐. 中华血液学杂志,第17卷第5期. 1996 * |
Sensitivity of human multiple myelomas and myeloidleukemias to the proteasome inhibitor I. F Servida等.Leukemia,No.19. 2005 |
Sensitivity of human multiple myelomas and myeloidleukemias to the proteasome inhibitor I. F Servida等. Leukemia,No.19. 2005 * |
The t(1,12)(q21,p13) translocation of human acutemyeloblastic leukemia results in a TEL-ARNT fusion. Florence Salomon-Nguyen等.PNAS,Vol.97 No.12. 2000 |
The t(1,12)(q21,p13) translocation of human acutemyeloblastic leukemia results in a TEL-ARNT fusion. Florence Salomon-Nguyen等. PNAS,Vol.97 No.12. 2000 * |
β-连环蛋白与白血病发病机制相关性研究进展. 陈胜梅.河南医学研究,第14卷第2期. 2005 |
β-连环蛋白与白血病发病机制相关性研究进展. 陈胜梅. 河南医学研究,第14卷第2期. 2005 * |
伴有成熟的急性髓细胞白血病(AML-M2)的形态学分型:成熟中性粒细胞胞浆中具有均一性粉红色为t(8 |
伴有成熟的急性髓细胞白血病(AML-M2)的形态学分型:成熟中性粒细胞胞浆中具有均一性粉红色为t(8;21)+AML-M2的最大特征. 沈美凤,薛永权. 国外医学输血及血液学分册,第21卷第1期. 1998 * |
Also Published As
Publication number | Publication date |
---|---|
CN1824288A (zh) | 2006-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lesan et al. | Evaluation of antagonistic effects of metformin with Cisplatin in gastric cancer cells | |
Wang et al. | Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment | |
Keung et al. | Chronic myelocytic leukemia with eosinophilia, t (9; 12)(q34; p13), and ETV6-ABL gene rearrangement: case report and review of the literature | |
WO2008089645A1 (fr) | Polypeptide de fusion inhibant la croissance cellulaire et son utilisation | |
CA2818933A1 (en) | Phosphaplatins having anti-angiogenic, anti-metastatic, and pro-apoptotic properties and uses thereof | |
CN101716167B (zh) | 一类饱和胺类化合物在制备外周血造血干细胞动员药物中的应用 | |
Yamashita et al. | Anti-diabetic drug metformin inhibits cell proliferation and tumor growth in gallbladder cancer via G0/G1 cell cycle arrest | |
Chu et al. | Better clinical efficiency of TILs for malignant pleural effusion and ascites than cisplatin through Intrapleural and intraperitoneal infusion | |
Zhou et al. | Calycosin enhances some chemotherapeutic drugs inhibition of Akt signaling pathway in gastric cells | |
CN100372568C (zh) | 化合物mg-132在制备治疗白血病药物中的应用 | |
CN100448479C (zh) | 化合物psi在制备治疗白血病药物中的应用 | |
CN103145867A (zh) | 一种抗肿瘤生物多糖 | |
CN102153657A (zh) | IL-24-Tat PTD融合蛋白及其构建方法和应用 | |
CN100441222C (zh) | 化合物ps-341在制备治疗急性髓性白血病药物中的应用 | |
CN110452162A (zh) | 一种查尔酮衍生物作为Fli-1基因靶向调节剂的应用 | |
CN107537027A (zh) | Tnfsf15蛋白在制备治疗黑色素瘤药物中的用途 | |
Xiao et al. | Silencing Fas-associated phosphatase 1 expression enhances efficiency of chemotherapy for colon carcinoma with oxaliplatin | |
CN101688205B (zh) | 抗肿瘤药物、药剂、组合物及其用途 | |
CN103417988B (zh) | Cdk2基因在制备白血病诱导分化治疗药物中的应用 | |
CN100364607C (zh) | 化合物ps-341在制备治疗慢性粒细胞性白血病的药物中的应用 | |
KR20140035974A (ko) | 종양 질환 치료를 위한 약제 조성물 | |
Niu et al. | ARHGEF19 promotes the growth of breast cancer in vitro and in vivo by the MAPK pathway | |
CN1961890A (zh) | 二丁酰环磷酸腺苷钙在制药中的用途 | |
Zhang et al. | Prognostic Impact of Aberrantly Expressed Proteincoding Gene Associated With Gastric Cancer’s Regulatory T Cells, Based on Online Databases. | |
Yuan et al. | Liposome-mediated induction of apoptosis of human hepatoma cells by c-myc antisense phosphorothioate oligodeoxynucleotide and 5-fluorouracil |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: CHINESE ACADEMY OF SCIENCES GUANGZHOU INSTITUTE O Free format text: FORMER OWNER: ZHOU GUANGBIAO Effective date: 20071228 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20071228 Address after: International Business Incubator of Science City, Guangdong, Guangzhou Province, China: 510663 Applicant after: Guangzhou Biomedicine and Health Inst., Chinese Academy of Sciences Address before: Guangzhou Guangdong Science City International Business Incubator, Chinese Academy of Sciences, Guangzhou Institute of biological medicine and health, postal code: 510663 Applicant before: Zhou Guangbiao |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090107 Termination date: 20100111 |